Filing Flows › Adma Biologics (ADMA) › Q2 2026 › vs Q1 2026
Adma Biologics (ADMA) Q2 2026 vs Q1 2026 (quarter over quarter)
Adma Biologics's revenue rose $9.9M (+9%) from $114M in Q1 2026 to $124M in Q2 2026. The biggest changes: ADMABio Manufacturing Segment +$9.9M (+9%); Plasma Collection Centers Segment +$7K (+1%). Gross margin 69.4% against 70.5% (-1.2 pts).
Adma Biologics, Q2 2026: revenue $124M (+2% year over year), operating margin 42.2%, net earnings $37.8M, operating cash flow $29.5M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 69.4% | 70.5% | -1.2 pts |
| Operating margin | 42.2% | 50.9% | -8.7 pts |
| Net margin | 30.4% | 39.6% | -9.2 pts |
| Free cash flow margin | 21.9% | 48.7% | -26.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| ADMABio Manufacturing Segment | $124M | $114M | $9.9M | +9% |
| Plasma Collection Centers Segment | $723K | $716K | $7K | +1% |
| Revenue | $124M | $114M | $9.9M | +9% |
| Gross profit | $86.3M | $80.8M | $5.5M | +7% |
| Cost of revenue | $38.1M | $33.7M | $4.4M | +13% |
| Operating profit | $52.4M | $58.3M | −$5.8M | -10% |
| Operating expenses | $33.8M | $22.5M | $11.4M | +51% |
| Pre-tax earnings | $50.2M | $57.1M | −$6.9M | -12% |
| Other expense, net | $2.2M | $1.1M | $1.1M | +93% |
| Net earnings | $37.8M | $45.3M | −$7.5M | -17% |
| Income tax | $12.4M | $11.8M | $616K | +5% |
| Depreciation & amortization | $1.7M | $1.8M | −$100K | -6% |
| Share-based compensation | $6.1M | $6.3M | −$194K | -3% |
| Working capital & other | $16.1M | −$4.8M | $20.9M | — |
| Operating cash flow | $29.5M | $58.2M | −$28.7M | -49% |
| Free cash flow (OCF − capex) | $27.3M | $55.7M | −$28.4M | -51% |
| Capital expenditures | $2.3M | $2.5M | −$287K | -11% |
Questions
How much did Adma Biologics's revenue grow quarter over quarter in Q2 2026?
Adma Biologics's revenue rose $9.9M (+9%) from $114M in Q1 2026 to $124M in Q2 2026.
What drove Adma Biologics's revenue change in Q2 2026?
ADMABio Manufacturing Segment +$9.9M (+9%); Plasma Collection Centers Segment +$7K (+1%).